Where Does Axatilimab Fit in the Treatment Lineup?
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
Video content above is prompted by the following questions:
- What were the key findings from the AGAVE-201 trial presented at the 2023 ASH meeting?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
December 12th 2024In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.
Read More
